Coffee is one of the world's most familiar drinks, and the question “can I drink coffee with multiple sclerosis?” comes up very often. In recent years, new systematic reviews, meta-analyses and a randomized trial of caffeine for fatigue in people with MS have been published.
The picture is interesting: observational studies associate coffee consumption with a lower probability of developing MS, but genetic methods have not confirmed a causal protective effect. For established MS, evidence that coffee slows disability progression is limited, while in 2026 a controlled study produced a positive signal specifically for caffeine and fatigue.
Yes, this association appears in many observational studies. However, the size of the effect varies considerably, so these findings should not be translated into advice to “drink more coffee”.
Pooled odds ratio for developing MS among coffee consumers in a 2025 meta-analysis before adjustment for accompanying factors.
Adjusted odds ratio in the same meta-analysis. Heterogeneity between studies was very high.
Another 2025 meta-analysis also found a lower risk of MS among coffee consumers, again with substantial heterogeneity.
In a well-known analysis of two large case-control studies from Sweden and the United States, high coffee intake — more than approximately 900 mL per day — was associated with about a 30% lower odds of developing MS compared with no coffee consumption.
In many studies, MS was less common among people who regularly drank coffee. Some studies also suggested a relationship between the amount consumed and the strength of the association.
Genetic variants associated with habitual coffee intake did not confirm a causal reduction in MS risk: the odds ratio was approximately 1.00. In other words, a genetically influenced tendency to drink more coffee was not associated with a lower probability of developing MS.
Coffee consumption is associated with many other factors, including smoking, work patterns, sleep, diet, body weight and physical activity. Even good statistical analyses cannot perfectly eliminate all these differences.
The most accurate conclusion: coffee consumption is associated with a lower risk of MS, but there is no proof that coffee itself causally prevents the disease.
Coffee is not simply caffeine dissolved in water. It contains hundreds of biologically active compounds, and some potential effects may be related to components other than caffeine.
Caffeine primarily blocks A1 and A2A receptors. These systems are involved in wakefulness, neuronal signaling, microglial function and regulation of inflammatory responses.
Chlorogenic acids and other coffee components have antioxidant and potentially anti-inflammatory properties.
In experimental models, caffeine and other coffee components influence cytokines, microglia, the blood-brain barrier and neuronal survival.
The evidence here is considerably weaker than the evidence regarding the risk of developing MS.
In a Belgian study of 1,372 patients, regular coffee consumption was associated with a slower time to EDSS 6 in people whose MS began with a relapsing course. No such association was found in patients with progressive-onset disease.
However, later studies did not confirm a consistent relationship between the amount of coffee consumed, lifetime coffee exposure and MS severity.
The review included eight clinical studies of different designs. No convincing relationship between the amount of coffee consumed and disability level was identified. Therefore, it is not currently possible to say that coffee slows MS progression or PIRA.
Fatigue is one of the main reasons patients themselves notice a benefit from coffee. Until recently, this idea was based mainly on observations and small pilot studies.
Sixty patients with MS and fatigue received 100 mg of caffeine per day or placebo for 12 weeks.
MFI-20 decreased significantly more in the caffeine group: the between-group difference was −8.55 points. Vitality, physical functioning, emotional well-being and pain on the SF-36 also improved.
No serious adverse events were reported.
The study was small and lasted only 12 weeks. The result is interesting but needs independent replication in larger samples.
In addition, 100 mg of pure caffeine is not the same thing as an arbitrary amount of coffee.
In an earlier survey of 124 patients, coffee drinkers often reported better concentration, longer attention span and a more structured daily routine. These are subjective data, but they help explain why coffee can feel helpful even without any effect on MS disease activity.
Caffeine increases wakefulness, reduces subjective sleepiness and can temporarily improve attention and reaction speed in many people. This is a general pharmacological effect rather than a specific treatment for MS.
In the 2024 systematic review, cognitive and functional effects appeared more promising than effects on disability. However, studies were few, sample sizes were small and methods of assessment varied.
| Source | What matters | Practical meaning |
|---|---|---|
| Regular coffee | Caffeine, chlorogenic acids, polyphenols, melanoidins, diterpenes and other compounds. | Epidemiological studies usually examine coffee as a beverage rather than pure caffeine. |
| Decaffeinated coffee | Contains little caffeine but retains many other coffee components. | May be useful if you like coffee but caffeine worsens sleep, anxiety or palpitations. |
| Caffeine tablets | Provide a more predictable dose without the other components of coffee. | Useful in research, but this is not a reason to start supplements on your own. |
| Tea, mate and energy drinks | Also contain caffeine but have a different mixture of active compounds. | Data on coffee cannot automatically be applied to every caffeinated drink. |
Espresso, filter coffee, capsule coffee and instant coffee can contain very different amounts of caffeine. Therefore, a dose used in a clinical trial cannot simply be translated into “one cup”.
Caffeine can interfere with falling asleep and sleep quality. If a patient tries to treat fatigue with coffee but sleeps worse because of it, a vicious cycle can develop.
Sensitive individuals may experience inner tension, tachycardia and awareness of irregular heartbeats.
Caffeine can increase physiological tremor and may make pre-existing tremor more noticeable in some patients.
A large beverage volume and caffeine may increase urinary frequency and urgency in some patients.
Coffee may worsen reflux, heartburn, dyspepsia or loose stools in sensitive individuals.
Caffeine can transiently increase blood pressure, especially in people who do not consume it regularly.
No. Even the recent meta-analyses are based mainly on observational data, and a causal protective effect has not been proven.
If a person has long enjoyed coffee, tolerates it well and has no contraindications, an MS diagnosis is not a reason to stop.
Long-term MS prognosis is determined by much more important factors: appropriate disease-modifying therapy, smoking cessation, physical activity, weight control, sleep and management of vascular risk factors.
Coffee is therefore better viewed as one element of diet and everyday life, rather than as a separate “neuroprotective therapy”.
If fatigue has become significant, it is important not to rely only on caffeine, but to assess sleep, medications, deficiencies, mood, accompanying symptoms and MS activity.
Material updated September 2026.